āshibio, a privately held biotechnology company based in Burlingame, California, announced on October 13, 2026, new clinical biomarker findings showing that vantictumab increased a marker of bone resorption by more than 25% in 29 of 31 patients previously treated in a Phase 1 cancer study. The company also presented genetic research estimating the prevalence of CLCN7-related autosomal dominant osteopetrosis type 2 (ADO2) at between one and four individuals per 20,000 people, potentially supporting a broader patient population than has historically been recognised. Both analyses were presented at the American Society for Bone and Mineral Research annual meeting in Boston and support the development rationale for an investigational antibody that āshibio now intends to test in ADO2 patients during the first half of 2028.
The biomarker findings provide human evidence that vantictumab can influence pathways involved in bone resorption, a process impaired in patients with ADO2. However, the 31 participants had advanced cancer rather than osteopetrosis, and the findings demonstrate a pharmacodynamic response rather than clinical improvement in genetic bone disease. The distinction is especially important because earlier oncology development identified fragility fractures in some patients associated with increased bone turnover, creating a safety question for a medicine intended to modify bone remodelling.
The genetic analysis addresses a separate challenge in rare disease development: determining how many people may have the condition. āshibio used large international genetic datasets, disease-associated CLCN7 variants and assumptions about how frequently those variants produce clinical disease to estimate prevalence. The company believes the findings support a potential population of approximately 40,000 affected individuals across the United States, Europe and Japan, although this remains an estimated disease population rather than a verified number of patients eligible for treatment.
What do the 94% vantictumab biomarker findings establish about osteoclast activation?
The new analysis examines bone turnover measurements collected during an earlier first-in-human investigation of vantictumab in patients with advanced solid tumours. Researchers assessed C-terminal telopeptide of type I collagen, known as βCTX, a blood biomarker associated with the breakdown of bone collagen during osteoclast-mediated resorption. Of the 31 patients evaluated, 29 experienced an increase in βCTX exceeding 25% from baseline, while 23 patients, representing 74%, experienced increases of at least 50%.
These findings support the conclusion that vantictumab can produce measurable changes in human bone turnover. The response was observed after administration of doses ranging from 0.5 mg/kg to 5 mg/kg, with treatment schedules including once-weekly dosing and administration every two or three weeks. āshibio reported an exposure-response relationship, suggesting that dose and dosing interval may influence the magnitude of the biological effect.
The lower-dose findings are particularly relevant to the planned ADO2 programme. Among patients receiving once-weekly doses of 0.5 mg/kg or 1 mg/kg, which overlap with the upper end of the dose range predicted from animal research, investigators observed elevated βCTX measurements at day 28. These observations support further evaluation of whether lower exposures can produce the desired pharmacological activity without generating excessive bone resorption.
The company also examined procollagen type I N-terminal propeptide, or P1NP, a marker associated with bone formation. Comparative analysis of βCTX and P1NP suggested that lower vantictumab doses could increase bone resorption without a corresponding suppression of bone formation. This provides a potentially useful pharmacological distinction, although circulating biomarkers do not directly establish normal osteoclast function, improved bone architecture or reduced fracture risk.
The findings remain exploratory because the original Phase 1 study was conducted for oncology drug development rather than ADO2 treatment. The patients did not have the genetic osteoclast dysfunction characteristic of the intended population, and the analysis was not designed to establish a clinically effective dose for osteopetrosis. The results demonstrate target-related biological activity in humans, not proof that vantictumab can correct the underlying disease.
How could blocking Frizzled receptors help restore abnormal bone remodelling in ADO2?
Autosomal dominant osteopetrosis type 2, also known as Albers-Schönberg disease, is an inherited disorder in which bone-resorbing osteoclasts function inadequately. The condition is commonly associated with pathogenic variants in CLCN7, a gene involved in chloride transport and the acidification processes required for normal osteoclast activity. When osteoclasts cannot remove bone effectively, bone tissue accumulates abnormally and normal skeletal remodelling becomes disrupted.
This can produce the seemingly contradictory combination of unusually dense and fragile bones. Patients may experience recurrent fractures, delayed healing, bone infections, dental complications and nerve compression resulting from abnormal skeletal growth. In more severely affected individuals, reduced space within the bone marrow can also contribute to blood cell abnormalities.
Vantictumab is a monoclonal antibody that binds selected Frizzled receptors and inhibits components of the WNT signalling pathway. WNT signalling participates in the regulation of skeletal development and bone remodelling, including interactions between bone-forming osteoblasts and bone-resorbing osteoclasts. By modifying this pathway, āshibio aims to increase osteoclast activity sufficiently to restore a more balanced remodelling process.
The objective differs from conventional osteoporosis treatment. Osteoporosis is commonly associated with reduced bone strength and often excessive bone loss relative to formation, while ADO2 involves defective resorption and abnormal accumulation of dense skeletal tissue. A medicine that increases bone breakdown could therefore have a therapeutic rationale in ADO2, even though excessive bone resorption would be undesirable in many other skeletal conditions.
However, achieving the correct balance is essential. Excessively stimulating osteoclasts could compromise bone strength rather than improve it, particularly if bone formation does not keep pace with resorption. Clinical development must therefore establish whether vantictumab can improve skeletal quality within a therapeutic window that avoids excessive bone loss.
Why do the previous oncology fractures remain a major safety consideration for vantictumab?
Vantictumab was originally developed as an anticancer therapy and was evaluated in approximately 100 patients across several Phase 1a and Phase 1b oncology investigations between 2011 and 2017. Its development history provides valuable information about human exposure, pharmacokinetics and biological activity. Nevertheless, the earlier programme also identified increased bone turnover and fragility fractures in some patients, as disclosed by development partner Mereo BioPharma Group plc.
These findings are important because the pharmacological effect now being pursued in ADO2 was previously associated with clinically undesirable skeletal consequences in a different population. Cancer patients may also have additional risk factors for fractures, including underlying disease, previous treatments and impaired skeletal health. The earlier events therefore require careful interpretation rather than establishing that the same outcomes would necessarily occur with lower-dose treatment in ADO2.
āshibio believes dose selection may provide a route to a more favourable therapeutic balance. Victoria Smith, the company’s chief scientific officer, reported that the biomarker findings support adjusting vantictumab exposure to stimulate bone resorption while potentially preserving bone formation. The company also described nonclinical toxicity modelling suggesting a therapeutic index with margins of up to 200-fold.
That margin is a company-derived preclinical prediction, not a demonstrated 200-fold safety margin in patients with ADO2. Its reliability will depend on whether the exposure-response relationships observed in animals and oncology patients translate to the intended disease population. The earlier fracture experience makes prospective monitoring of skeletal integrity particularly important, even if initial biomarker responses appear favourable.
The reported half-life of approximately 3.5 days offers another potentially relevant characteristic. āshibio observed that βCTX levels declined relatively rapidly after vantictumab administration stopped, suggesting that the pharmacodynamic effect responds to changes in drug exposure. This could support dose adjustment during clinical development, but reversibility of a blood biomarker does not necessarily establish that structural bone changes or adverse events would reverse equally quickly.
What did the 2025 ADO2 mouse experiments demonstrate about vantictumab’s potential efficacy?
The newest human biomarker findings follow preclinical results presented at the 2025 American Society for Bone and Mineral Research meeting. In that research, āshibio and academic collaborators evaluated vantictumab in mice carrying a genetic abnormality associated with ADO2. Treatment reduced elevated bone mineral density and improved several measures of skeletal architecture and quality.
The findings provided evidence that modifying WNT signalling could influence the abnormal bone phenotype associated with impaired osteoclast function. They also supported the biological rationale for investigating the antibody at doses intended to improve resorption without causing excessive skeletal deterioration. The subsequent human biomarker analysis adds evidence that the antibody affects relevant bone-remodelling pathways in people.
However, improvement in bone mineral density requires careful interpretation in osteopetrosis. A reduction in abnormally elevated density may reflect movement towards more normal skeletal architecture, but a decline in density is not automatically synonymous with increased bone strength. Clinical studies must examine structural and functional outcomes rather than treating density reduction alone as proof of disease modification.
The animal findings also cannot establish that the medicine prevents fractures, improves healing or reverses neurological complications in patients. Genetic background, disease progression and the response to WNT inhibition can differ between experimental models and humans. The two evidence streams now provide a rationale for clinical investigation, but neither demonstrates treatment efficacy in people living with ADO2.
How was the new CLCN7-related ADO2 prevalence estimate of 1–4 per 20,000 calculated?
The second presentation at ASBMR examined the possible frequency of CLCN7-related ADO2 using large international genetic datasets. Investigators analysed version 4.1.1 of the Genome Aggregation Database, drawing on previously reported disease-associated variants and pathogenic or likely pathogenic classifications supported by clinical information from ClinVar. The objective was to estimate the frequency of genetic changes associated with the disease rather than rely exclusively on diagnosed cases.
The research produced an estimated prevalence ranging from one to four affected individuals per 20,000 people, depending on the variant inclusion criteria. This corresponds to approximately five to 20 individuals per 100,000, illustrating how the assumptions used in genetic prevalence modelling can substantially influence the resulting population estimate. The figures are estimates derived from genetic evidence rather than a direct count of clinically diagnosed ADO2 patients.
A particularly important assumption was disease penetrance. The researchers used an estimated penetrance of 66%, recognising that not every person carrying a disease-associated variant will necessarily develop recognisable clinical manifestations. Variation in penetrance and disease severity complicates the conversion of genetic variant frequency into estimates of patients requiring treatment.
Deborah Wenkert, āshibio’s chief medical officer, indicated that the investigators also tested the effect of excluding the R657Q variant, which was the most frequently represented ADO-associated CLCN7 variant in the analysed database. This sensitivity analysis was intended to assess whether assumptions about one relatively common variant were disproportionately influencing the overall estimate. The company concluded that the results remained broadly consistent with, or above, historical prevalence estimates.
Earlier estimates of autosomal dominant osteopetrosis frequently cited approximately one affected individual per 20,000 births, based on a 1988 study using hospital records from Funen County, Denmark. The new analysis offers a different method based on contemporary genetic datasets and should not be interpreted as a direct measurement of increasing disease incidence. Differences in ascertainment, geography, penetrance and the definition of affected individuals can influence comparisons between historical and modern estimates.
Does the estimated 40,000-patient population represent a realistic commercial market?
āshibio believes the genetic analysis supports an estimated lower bound of approximately 40,000 individuals with ADO2 across the United States, Europe and Japan. This provides a preliminary basis for evaluating the potential size of a future treatment market. However, the estimate should not be interpreted as the number of patients currently diagnosed, clinically eligible for vantictumab or likely to receive treatment.
Disease severity varies substantially among people with CLCN7-related ADO2. Some patients may experience recurrent fractures or other debilitating complications, while others have relatively mild manifestations or remain undiagnosed. A treatment requiring repeated antibody administration and substantial monitoring may be considered differently across these groups, depending on its eventual demonstrated benefits and risks.
Commercial estimates must also account for genetic diagnosis rates, healthcare access and the availability of specialist bone disease centres. Identifying additional individuals through genetic testing could improve understanding of disease burden, but molecular findings alone would not establish the need for pharmaceutical intervention. Regulators and payers would require evidence that treatment produces meaningful clinical benefits in the populations for which it is proposed.
The estimate also creates practical questions for clinical trial recruitment. A disease may affect thousands of individuals across multiple countries while remaining difficult to study because patients are geographically dispersed and relatively few specialist centres manage substantial numbers of cases. Establishing registries, genetic referral pathways and consistent eligibility criteria could therefore become an important part of the development programme.
Why does Mereo BioPharma’s licensing agreement matter for vantictumab development?
Vantictumab entered āshibio’s portfolio through an August 2025 licensing agreement with Mereo BioPharma Group plc (NASDAQ: MREO), a publicly traded rare disease biotechnology company. Under the arrangement, āshibio assumed responsibility for funding and conducting global clinical development. Mereo retained commercial rights in Europe and the United Kingdom, while āshibio holds commercial rights in the United States and other markets outside those territories.
The structure allows āshibio to advance the medicine into a new indication while giving Mereo a continuing economic interest without requiring it to fund the global clinical programme directly. The agreement includes contingent milestones and royalty arrangements, whose eventual value will depend on development progress, regulatory decisions and commercial sales. No milestone payment or new financing transaction was disclosed in the October 13 biomarker announcement.
Mereo’s previous disclosures also make the compound’s safety history particularly relevant. The company has acknowledged that higher bone turnover during the oncology programme contributed to fragility fractures in some patients. The new dose-response findings could inform how āshibio approaches this risk, but they do not remove the underlying concern.
The market implications for Mereo are therefore indirect and longer-term. Its American depositary shares closed at approximately $0.32 on October 12, 2026, after declining 9.9% during that session. Because the biomarker announcement was issued the following day, the October 12 movement cannot be attributed to the new ASBMR findings.
For āshibio, the commercial significance is also developmental rather than immediate. The company remains privately held, and vantictumab has not generated approved ADO2 treatment revenue. Its value will depend on whether clinical studies establish a reproducible benefit-risk profile and whether the resulting evidence supports regulatory approval.
Why has āshibio moved its planned ADO2 clinical study to the first half of 2028?
The October 13 announcement identifies the first half of 2028 as āshibio’s planned period for advancing vantictumab into clinical trials involving patients with ADO2. This is later than the 2026 development timelines described in earlier company and Mereo disclosures. Neither the latest announcement nor the available supporting information provides a specific explanation for the change.
The revised timetable makes it particularly important to distinguish previous clinical exposure in oncology patients from clinical development in ADO2. Vantictumab has already been administered to humans, but the planned study would investigate its use in people with the genetic bone disorder for which the company now seeks to develop it. The dose, treatment schedule, endpoints and safety monitoring requirements for that investigation have not been fully disclosed.
An ADO2 programme will likely need to assess changes in bone turnover alongside structural measures and clinically relevant outcomes. Fracture frequency, skeletal complications, pain, functional capacity and bone quality could all contribute to understanding treatment effects, although no definitive endpoint framework has been announced. Selecting endpoints will be challenging because changes in bone architecture may develop gradually and clinical complications may occur relatively infrequently within a small study.
The forthcoming trial will also need to establish a dosing strategy that produces enough osteoclast activity to improve abnormal remodelling without creating excessive bone loss. The Phase 1 biomarker findings could guide that process, particularly by identifying exposure ranges associated with measurable biological activity. However, dose selection based on biomarkers will still require confirmation of tolerability and appropriate pharmacological effects in ADO2 patients.
Regulatory discussions will determine the requirements for advancing the programme, and the latest announcement does not establish that a new ADO2 trial has started or that marketing authorisation is under review. Vantictumab remains an investigational therapy without an approved ADO2 indication.
What will determine whether vantictumab becomes a disease-modifying treatment for ADO2?
ADO2 currently lacks an approved disease-specific pharmacological treatment that reliably corrects its underlying osteoclast dysfunction. Clinical care generally focuses on monitoring skeletal health and managing complications such as fractures, dental disease, infections, blood cell abnormalities and nerve compression. This creates a meaningful development opportunity for a medicine that could improve skeletal remodelling rather than addressing individual complications after they occur.
The October 2026 findings strengthen the biological rationale for vantictumab by connecting three separate elements: previously observed improvement in an ADO2 mouse model, increased bone-resorption biomarkers in human oncology patients and a genetic prevalence analysis suggesting a potentially larger affected population. Each contributes useful information, but none establishes that the treatment improves clinical outcomes in ADO2 patients.
The most consequential uncertainty concerns whether the desired pharmacological effect can be separated from the skeletal toxicity previously observed in oncology development. Changes in βCTX and P1NP can help investigators understand bone remodelling, but they cannot independently determine whether treated bones become stronger, heal more effectively or experience fewer fractures. Those questions require prospective clinical evidence.
The genetic prevalence findings will support planning for patient identification and eventual commercial evaluation, but they also introduce uncertainty concerning penetrance and clinical severity. An estimated 40,000 affected individuals across major developed markets does not mean that every person would qualify for treatment or benefit from the same dose. A successful development strategy will need to match the medicine’s effects with a clearly defined patient population.
āshibio’s next meaningful milestone is the planned initiation of ADO2 clinical testing in the first half of 2028. The company now has stronger evidence that vantictumab can influence bone turnover in humans and a more detailed estimate of the genetic population it hopes to serve. Whether this approach can become a genuine disease-modifying treatment will depend on demonstrating that controlled activation of osteoclasts improves skeletal health without recreating the fracture risks that complicated the antibody’s earlier oncology development.
